Aghili M, et al. - In this randomized, placebo-controlled, double-blinded clinical trial, researchers investigated the efficacy of gabapentin for chemotherapy-induced neuropathy prevention. Study participants—women with breast cancer—were randomly allocated to one of two groups: paclitaxel chemotherapy with oral gabapentin 300 mg three times daily or placebo for 2 weeks beginning at day 1 of each paclitaxel cycle. Findings supported the efficacy of gabapentin given with paclitaxel for the prevention of intermediate and high-grade neuropathies—both objectively and subjectively.